drugset / Trial / NCT05435313
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open-label clinical study, to explore the efficacy and safety of fruquintinib combined with tislelizumab and HAIC (hepatic arterial infusion chemotherapy) in patients with colorectal liver metastases cancer (CRLM) who failed standard therapy.
Timeline
- Start
- 2022-07-12
- Primary completion
- 2024-01
- Completion
- 2024-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | Irinotecan | Small molecule | 120 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | Raltitrexed | Small molecule | 2 mg/m2 | Other |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |